Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 2	2026-08-07		NCT03439735

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Biovica International AB	1
Safeway Foundation	2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	117

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Johns Hopkins University	Baltimore	United States	150

Clinical trials